QIAGEN Launches "Digital NGS" Solutions with Unique Molecular Index Technology to Reliably Detect All Genetic Variation

QIAseq Targeted NGS panels deliver highly sensitive, unbiased and accurate NGS insights

27 Jul, 2016, 16:07 ET from QIAGEN N.V.

HILDEN, Germany and GERMANTOWN, Maryland, July 27, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of a comprehensive portfolio of novel QIAseq NGS panels based on a new and proprietary "Digital NGS" technology allowing unbiased, accurate quantification of DNA, RNA and miRNA with next-generation sequencing (NGS). Digital NGS leverages a novel unique Molecular Index Technology enabling more accurate quantification and detection of molecular variants across all sequencing platforms.

Coupled with advanced primer design and proprietary assay chemistry, the QIAseq Targeted panels enable reliable detection of extremely rare (low-frequency) mutations as well as highly efficient sequencing of GC-rich regions. In addition, this approach ensures accurate identification and quantitation of otherwise frequently undetected genetic variations. These features address important, previously only poorly addressed customer needs.

The QIAseq panels are incorporated into highly integrated Sample to Insight workflows, which include cloud-based bioinformatics for advanced data analysis and interpretation. They can be used for all common sample types and are available for various commercial NGS platforms. The assay roadmap for QIAGEN's GeneReader NGS System also builds on Digital NGS, adding another, very unique advantage to this fully automated NGS workflow solution.

Click here for full press release


Public Relations: Dr. Thomas Theuringer Senior Director Public Relations +49 2103 29 11826 Email: pr@qiagen.com www.twitter.com/qiagen https://www.facebook.com/QIAGEN pr.qiagen.com Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49 2103 29 11711 Email: ir@qiagen.com ir.qiagen.com